

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Review Proposal Project

#### NICE Technology Appraisal No. 199; Etanercept, Infliximab, and Adalimumab for the treatment of psoriatic arthritis, and No. 220; Golimumab for the treatment of psoriatic arthritis

#### Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• AbbVie Limited (adalimumab)</li> <li>• Merck Sharp &amp; Dohme (infliximab and golimumab)</li> <li>• Pfizer (etanercept)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Pain</li> <li>• Afiya Trust</li> <li>• Arthritic Association</li> <li>• Arthritis and Musculoskeletal Alliance</li> <li>• Arthritis Care</li> <li>• Arthritis Research UK</li> <li>• Black Health Agency</li> <li>• Disability Rights UK</li> <li>• Equalities National Council</li> <li>• Independent Age</li> <li>• Leonard Cheshire Disability</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Pain Concern</li> <li>• Pain UK</li> <li>• Psoriasis and Psoriatic Arthritis Alliance</li> <li>• Psoriasis Association</li> <li>• Psoriasis Help Organisation</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Bone Research Society</li> <li>• British Association for Services to the Elderly</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Healthcare Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• Actavis UK (azathioprine, leflunomide, sulfasalazine)</li> <li>• Arrow Generics (azathioprine)</li> <li>• Aspire Pharma (leflunomide)</li> <li>• GlaxoSmithKline (azathioprine)</li> <li>• Medac UK (leflunomide)</li> <li>• Mercury Pharma (methotrexate)</li> <li>• Mylan UK (azathioprine, sulfasalazine)</li> <li>• Novartis Pharmaceuticals (ciclosporin)</li> <li>• Orion Pharma UK (methotrexate)</li> </ul>

National Institute for Health and Care Excellence  
 NICE Technology Appraisal No. 199; Etanercept, Infliximab, and Adalimumab for the treatment of psoriatic arthritis, and No. 220; Golimumab for the treatment of psoriatic arthritis  
 Issue date: June 2013

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• British Association of Dermatologists</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> <li>• British Health Professionals in Rheumatology</li> <li>• British Institute of Musculoskeletal Medicine</li> <li>• British Orthopaedic Association</li> <li>• British Society for Rheumatology</li> <li>• British Society of Rehabilitation Medicine</li> <li>• Physiotherapy Pain Association</li> <li>• Primary Care Dermatology Society</li> <li>• Primary Care Rheumatology Society</li> <li>• Rheumatoid Arthritis Surgical Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS England</li> <li>• NHS Newbury &amp; District CCG</li> <li>• NHS Sheffield CCG</li> <li>• Welsh Assembly Government</li> </ul>	<ul style="list-style-type: none"> <li>• Pfizer (methotrexate, sulfasalazine)</li> <li>• Sandoz (azathioprine, leflunomide, methotrexate)</li> <li>• Sanofi (leflunomide)</li> <li>• Teva UK (azathioprine, leflunomide, methotrexate, sulfasalazine)</li> <li>• Wockhardt UK (methotrexate)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Epidermo-Epidemiology Society</li> <li>• Chronic Pain Policy Coalition</li> <li>• Cochrane Musculoskeletal Group</li> <li>• Cochrane Skin Group</li> <li>• Health Research Authority</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Pain Relief Foundation</li> <li>• Research Institute for the Care of Older People</li> <li>• Skin Research Centre</li> <li>• Skin Treatment &amp; Research Trust</li> </ul> <p><u>Assessment group</u></p> <ul style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guideline Centre</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

#### PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Care Excellence  
 NICE Technology Appraisal No. 199; Etanercept, Infliximab, and Adalimumab for the treatment of psoriatic arthritis, and No. 220; Golimumab for the treatment of psoriatic arthritis  
 Issue date: June 2013

## **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

### Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.